Continued Process Verification for COVID-19 Vaccine Formulation and Packaging (recombinant)

Abstract

period of less than 1 year of production, as 391 batches were produced. All variables evaluated are under control or on alert. As this is a new product, it is understood that some variations may be inherent to the process and therefore, all will continue to be evaluated on a quarterly basis until completing the period of one more year for the evaluation of phase 3b of the CPV.